Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The Group will continue to make proactive investments of its management resources in the life science business
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Subscribe To Our Newsletter & Stay Updated
